| 证券代码 | GNCA.O |
| 证券名称 | Genocea Biosciences Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-02-05 |
| 首发价格(元) | 12 USD |
| 首发数量(股) | 5500000 |
| 首发募资额(元) | 66,000,000.00 USD |
| 首发主承销商 | Citigroup Global Markets Inc,Cowen and Company, LLC |
| 货币单位 | USD |
| 公司名称 | Genocea Biosciences, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 100 Acorn Park Drive, Cambridge, Massachusetts, USA |
| 成立日期 | 2006-08-16 |
| 董事会主席 | Kenneth M. Bate |
| 公司属地 | United States 美国 |
| 公司网址 | www.genocea.com |
| 电话 | +1 (617) 876-8191 |
| 传真 | +1 (617) 500-0969 |
| 公司简介 | Genocea Biosciences, Inc.'s mission is to help conquer cancer by designing and delivering targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop cancer vaccines and immunotherapies. Genocea is currently studying the safety, immunogenicity, and efficacy of its lead neoantigen cancer vaccine, GEN-009, in a Phase 1/2a clinical trial. |